Supercomputers Race To Meet Petaflop Challenge: Page 3 of 5

Still unsettled is whether the computer industry can develop new designs that overcome performance limits of off-the-shelf supercomputers, while pleasing big-science government users and the time-constrained private sector at the same time. David Shaw, chairman of the D.E. Shaw Group, an investment and technology-development company that applies computational techniques to financial trading, isn't positive it can. "If we have to develop novel architectures to achieve world leadership in supercomputing, is there enough commonality between national and commercial needs to support a common architecture for both?" he asks. "We don't fully know the answer." Shaw, a former computer-science professor and Clinton administration technology adviser, is involved in a supercomputing survey of big companies being fielded by the Council on Competitiveness. Regardless of whether science and business are aligned, Shaw says, both fields are reaching the point that "hooking commercial microprocessors together" isn't enough to solve all emerging problems in defense, intelligence, drug design, and materials science.

Include finance in the mix as well. One technologist on Wall Street says his company will probably manage 1 million networked computing devices within five years and is going to need high-performance computers that can grow to handle them. "Blue Gene is right on the money for us," he says. "We'd like to trade away from clock speed, power consumption, and cooling if we could. Heck, we'd take that in a heartbeat."

Not so fast, some experts say. The specialized architectures IBM and Cray say will reach a petaflop first are so hard to develop software for, there aren't likely many companies that will need that much juice. "If they could get certain kinds of database apps to run on [Blue Gene], that would be interesting to CIOs," says Larry Smarr, director of the California Institute for Telecommunications and Information Technology and founder of the National Science Foundation's supercomputing program. "The problem with specialized architectures is it takes too long" to develop software.

Merck & Co. is a big user of supercomputers from IBM, Sun, and others in its research division, which tests new molecular compounds for their efficacy as potential drugs. Company scientists have their eyes on Blue Gene, but historic milestones don't mean much to them. "The petaflop in and of itself isn't enough to gain our enthusiasm," says Irene Qualters, VP for research information systems. "It has to be a sustainable architecture we can invest in over the long haul." In many cases, traditional wet-lab instruments yield cheaper, better results than computer simulations, adds senior computing director Jeff Saltzman. "Blue Gene is a long-term investment with an uncertain probability of success," Saltzman says. "We're a moving target as far as our requirements. If we can't compute it, then we'll do experiments."

Yet it's not just biotech, aerospace, and finance companies that depend on superpowerful computers. Procter & Gamble Co., for example, used Silicon Graphics Inc.'s newest Altix 3000 supercomputer to design a new aroma-preserving container for Folgers coffee that costs about $7. Advocates of government support for the supercomputing effort contend it's that kind of tech-enabled innovation that will allow U.S. industry to compete with nations such as China, where wages are lower. "The worst thing we can do is think we can compete in advanced manufacturing with low wages," says Council on Competitiveness president Wince-Smith, a former technology policy adviser in the Reagan and first Bush administrations. "We'll compete in rapid prototyping using high-end computing."